计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| R650355-5mg |
5mg |
期货 ![]() |
| |
| R650355-10mg |
10mg |
期货 ![]() |
| |
| R650355-25mg |
25mg |
期货 ![]() |
| |
| R650355-50mg |
50mg |
期货 ![]() |
| |
| R650355-100mg |
100mg |
期货 ![]() |
|
| 别名 | RORγt 反向激动剂 13 |
|---|---|
| 规格或纯度 | ≥99% |
| 英文名称 | RORγt inverse agonist 13 |
| 生化机理 | RORγt 反向激动剂 13(化合物 3i)是一种强效、具有口服活性和选择性的 RORγt 反向激动剂,具有改进的类似药剂特性,其 IC 50 为 63.8 nM。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist, with improved agent-like properties, with an IC 50 of 63.8 nM In Vitro RORγt inverse agonist 13 (Compound 3i) exhibits activity with an inhibition of 76% at 0.3 µM in Th17 cell differentiation assay. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo RORγt inverse agonist 13 (Compound 3i, 25 mg/kg, Orally, twice daily) demonstrats excellent in vivo PK profile in mice and good in vivo efficacy in an IMQ-induced psoriasis mice model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Imiquimod (IMQ)-induced psoriasis mice model . Dosage: 25 mg/kg. Administration: Orally, twice daily. Result: Brought in a significant reduction in clinical severity of psoriasis as measured through the ear erythema, back skin erythema and scaliness scales. Animal Model: Male CD-1 Mice . Dosage: 1 mg/kg (i.v.) and 5 mg/kg (p.o.)(Pharmacokinetic Analysis). Administration: IV or PO, single dose. Result: C max : 609.67 ng/mL (PO), 1550 ng/mL (IV). T 1/2 : 3.63 h (PO), 3.04 h (IV). Form:Solid IC50& Target:ROR-γ 63.8 nM (IC 50 ) |
| 纯度 | ≥99% |
| Smiles | O=C(O)CC1=CC=C(CNC(NC2=CC(Cl)=C(C3=CC=CC=C3OC(F)(F)F)C(Cl)=C2)=O)C=C1 |
|---|---|
| 分子量 | 513.29 |
| 溶解性 | DMSO : 100 mg/mL (194.82 mM; Need ultrasonic) |
|---|